Related Experiment Video
Updated: Jun 8, 2026
10:31
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
Myasthenia gravis.
Agnes Jani-Acsadi1, Robert P Lisak
1Department of Neurology, Neuromuscular Division, Wayne State University, School of Medicine, 8A University Health Center, 4201 St. Antoine, Detroit, MI, 48201, USA, aacsadi@med.wayne.edu.
Current Treatment Options in Neurology
|September 16, 2010
Summary
Acquired myasthenia gravis treatment requires personalized, evidence-based strategies. Management focuses on symptom control and addressing the autoimmune cause, with specific considerations for thymoma and ocular forms.
Area of Science:
- Neurology
- Immunology
- Autoimmune Diseases
Background:
- Acquired myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions.
- Treatment decisions must balance efficacy with patient-specific factors like severity, comorbidities, and quality of life.
Purpose of the Study:
- To outline evidence-based therapeutic approaches for acquired myasthenia gravis.
- To highlight individualized treatment considerations and management strategies for various MG presentations.
Main Methods:
- Review of current therapeutic options for acquired myasthenia gravis.
- Emphasis on personalized medicine, considering disease characteristics and patient factors.
- Discussion of surgical and medical management strategies, including immunosuppression and immunomodulation.
Main Results:
- Therapies aim to improve neuromuscular transmission and modulate the immune system.
- Surgical referral for operable thymoma is recommended.
- Evidence gaps exist for ocular myasthenia and thymectomy in specific patient groups.
Conclusions:
- Comprehensive management of acquired myasthenia gravis necessitates an individualized, evidence-based approach.
- Addressing thymoma, ocular manifestations, and myasthenic crisis requires tailored strategies.
- Patient education is crucial for effective long-term care.
Related Concept Videos
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...